Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 11, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance reported in this filing. The document details an increase in share interests for specific individuals following the re-investment of dividends paid on July 6, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports on the following transactions executed at a price of $56.46 per ADR:
- Dr. JP Garnier: 1,192.308 ADRs
- Dr. F Calhoun: 121.865 ADRs
- Mr. D Phelan: 229.960 ADRs
- Mr. D Stout: 91.916 ADRs
Investor Verification Points
- Verify the dividend reinvestment price of $56.46 per ADR against market data for July 6, 2006.
- Confirm the total number of ADRs acquired by the named directors under the Mid-Term Incentive Plan.
- Check subsequent filings for any changes in the ownership percentages of these individuals.